BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CTMSS - ECPv6.7.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CTMSS
X-ORIGINAL-URL:https://clinicaltmssociety.org
X-WR-CALDESC:Events for CTMSS
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20260101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260901T200000
DTEND;TZID=America/New_York:20260901T210000
DTSTAMP:20260910T230608
CREATED:20260810T204141Z
LAST-MODIFIED:20260811T145733Z
UID:4476-1788292800-1788296400@clinicaltmssociety.org
SUMMARY:EEG-guided TMS:  the State of the Evidence
DESCRIPTION:> >Register Now <<\nSpeaker: Andrew F. Leuchter\, MD\nTreatments for Major Depressive Disorder (MDD) act at different hierarchical levels of biological complexity\, ranging from the individual synapse to the brain as a whole. Evidence suggests that modulation of synchronized electrical activity in brain networks may integrate these different levels of complexity\, and may be central to the mechanism of action of repetitive Transcranial Magnetic Stimulation (rTMS). Several lines of research indicate that electroencephalogram (EEG) recording during rTMS can help elucidate the mechanism of action of rTMS treatment. There is emerging evidence that EEG also may be useful in guiding selection of EEG treatment parameters. This presentation will review data on whether EEG guidance of rTMS treatment can improve treatment outcomes for MDD or other neuropsychiatric disorders. \nKey learning objectives include:\n\nDiscuss the possible role of biomarkers to guide TMS treatment\nUnderstand the rationale for EEG measurement of the effects of EEG treatment\nExamine evidence supporting the use of EEG to guide clinical treatment\n\nTake advantage of our live Q&A session at the conclusion of the webinar. \n*Registered attendees will receive access to the on-demand video recording by Friday\, September 4\, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar. \nWhen: \nUSA - Sept 1\, 2026 at 8:00pm ET | 5:00pm PT\nUK- Sept 2\, 2026 at 1:00am BST\nAustralia- Sept 2\, 2026 at 10:00am AEST \nCost: \nMember: $25\nTrainee Member: FREE\nNon-Member: $50 \n> >Register Now <<\nAbout the Speaker \n \nAndrew F. Leuchter\, MD \nAndrew F. Leuchter\, MD\, is a Distinguished Professor of Psychiatry and Director of the Neuromodulation Division at UCLA. An expert on the treatment of mood disorders\, Dr. Leuchter directs the Transcranial Magnetic Stimulation (TMS) Clinical and Research Service. This is one of the largest academic TMS program in the country and treats patients with depression\, OCD\, pain\, tinnitus\, and other neuropsychiatric illness. His research aims to develop novel treatment strategies and predict which treatments are most likely to benefit individual patients.​ \nDr. Leuchter has authored over 200 scientific articles on topics including neuromodulation for the treatment of depression\, EEG biomarkers to guide treatment of neuropsychiatric illness\, and theories of antidepressant action. He teaches internationally on TMS and other neuromodulation methods.
URL:https://clinicaltmssociety.org/event/eeg-guided-tms-the-state-of-the-evidence/
CATEGORIES:Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2026/02/Untitled-design-44.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20261006T200000
DTEND;TZID=UTC:20261006T210000
DTSTAMP:20260910T230608
CREATED:20260910T223316Z
LAST-MODIFIED:20260910T223316Z
UID:4531-1791316800-1791320400@clinicaltmssociety.org
SUMMARY:From Sham-Controlled Trials to Real-World Practice: Making Sense of the TMS Evidence
DESCRIPTION:> >Register Now <<\nSpeakers: Tracy Barbour\, MD\, and Rebecca Allen\, MD\, MPH\, FCTMSS\nThis Grand Rounds provides a practical framework for evaluating TMS evidence—from randomized controlled trials through meta-analyses\, clinical guidelines\, and real-world practice. The speakers will examine study design\, statistical versus clinical significance\, generalizability\, and how clinicians can determine which intervention works\, for whom\, under what conditions\, and with what degree of certainty. \nKey learning objectives include:\n\nAnalyze key elements of randomized controlled trial methodology\, including sham conditions\, coil verification\, participant selection\, and outcome measures.\nDifferentiate statistical significance from clinical significance by considering effect sizes\, response and remission rates\, durability\, and applicability.\nIntegrate evidence from individual trials\, meta-analyses\, clinical guidelines\, regulatory approvals\, and real-world practice when evaluating TMS interventions.\n\nTake advantage of our live Q&A session at the conclusion of the webinar. \n*Registered attendees will receive access to the on-demand video recording by Friday\, October 9\, 2026. You will receive an email notification with instructions for accessing the video. You may register for the on-demand webinar any time after the live webinar. \nWhen: \nUSA - October 6\, 2026 at 8:00pm ET | 5:00pm PT\nUK- October 7\, 2026 at 1:00am BST\nAustralia- October 7\, 2026 at 11:00am AEST \nCost: \nMember: $25\nTrainee Member: FREE\nNon-Member: $50 \n> >Register Now <<\nAbout the Speakers\n  \nTracy Barbour\, MD\nProfessional Titles:Medical Director\, MGH TMS Clinical Service; Instructor in Psychiatry\, Harvard Medical School; Program Director\, MGH Interventional Neuropsychiatry and Neuromodulation Fellowship; President\, Clinical TMS Society \nAffiliations:Massachusetts General Hospital / Harvard Medical School; Boston Precision Neurotherapeutics \nBio: Tracy Barbour\, MD\, is Medical Director of the Transcranial Magnetic Stimulation (TMS) Clinical Service and Associate Director of the Electroconvulsive Therapy (ECT) Service at Massachusetts General Hospital\, and Instructor in Psychiatry at Harvard Medical School. She also serves as Program Director of the MGH Interventional Neuropsychiatry and Neuromodulation Fellowship and is co-owner of Boston Precision Neurotherapeutics\, a private practice specializing in fMRI-guided accelerated TMS. Her clinical and research work focuses on interventional psychiatry and the treatment of complex and treatment-resistant psychiatric disorders\, with particular expertise in TMS\, ECT\, and ketamine. Her research investigates biomarkers of neuromodulation response—including functional connectivity\, heart rate variability\, and alpha oscillations—toward advancing precision treatment selection in depression and related conditions. \nDr. Barbour is President of the Clinical TMS Society (CTMSS) and has previously served a Co-Chair of its Clinical Standards Committee. She currently contributes to both the Clinical Standards and Education Committees. She serves as Associate Editor of Transcranial Magnetic Stimulation\, the official journal of the CTMSS. She is an experienced educator in TMS and interventional psychiatry\, teaching clinicians through the CTMSS PULSES courses. \nRebecca M. Allen\, MD\, MPH\nProfessional Titles:Partner\, Director of Research | Seattle Neuropsychiatric Treatment CenterClinical Assistant Professor | University of WashingtonPast President 2023–24 | Clinical TMS SocietyPast President 2020–21 | Washington State Psychiatric Association \nAffiliations:Seattle Neuropsychiatric Treatment Center; University of Washington \nBio: Rebecca M. Allen\, MD\, MPH\, is Partner and Director of Research at Seattle Neuropsychiatric Treatment Center and Clinical Assistant Professor of Psychiatry and Behavioral Sciences at the University of Washington. A board-certified neuropsychiatrist\, her clinical and research work focuses on interventional psychiatry and the treatment of complex and treatment-resistant psychiatric disorders\, with particular expertise in TMS\, ECT\, ketamine and esketamine\, VNS\, and emerging psychedelic therapies. She serves as principal investigator for clinical trials evaluating novel pharmacologic and neuromodulation treatments for depression\, PTSD\, anxiety\, and other psychiatric disorders. Dr. Allen is a Past President of the Clinical TMS Society (2023–24) and has previously served as its Treasurer\, a member of its Board of Directors\, and Co-Chair of its Insurance Committee. She currently serves as Co-Chair of the Clinical Standards Committee. She is an experienced educator in TMS and interventional psychiatry\, teaching clinicians through the Clinical TMS Society’s PULSES courses and speaking on TMS\, neuromodulation\, and emerging treatments in psychiatry.
URL:https://clinicaltmssociety.org/event/from-sham-controlled-trials-to-real-world-practice-making-sense-of-the-tms-evidence/
CATEGORIES:Grand Rounds Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261015
DTEND;VALUE=DATE:20261016
DTSTAMP:20260910T230608
CREATED:20260623T145657Z
LAST-MODIFIED:20260623T145657Z
UID:4304-1792022400-1792108799@clinicaltmssociety.org
SUMMARY:Pain Academy San Diego
DESCRIPTION:
URL:https://clinicaltmssociety.org/event/pain-academy-san-diego/
CATEGORIES:Pain Academy
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2026/06/26-28-September-2025-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261023
DTEND;VALUE=DATE:20261026
DTSTAMP:20260910T230608
CREATED:20251205T204708Z
LAST-MODIFIED:20260810T204554Z
UID:3499-1792713600-1792972799@clinicaltmssociety.org
SUMMARY:PULSES Providence
DESCRIPTION:Course Overview\nThis in-depth training course offers a Certificate of Completion and features lectures and over 3 hours of hands-on training delivered by Clinical TMS Society renowned clinicians\, engineers\, and researchers\, along with special guests. Attendees will receive current\, historical\, and practical knowledge for treating patients with TMS based on the best available evidence. \nThe Program Includes:\n\nA review of the clinical studies that serve as the foundation for treatment of TMS for depression\, as well as clinically applicable research and current important studies.\nFour lectures on the practical administration of TMS for patients\, including practice setup to patient dosing\, scheduling\, and management.\nA review of protocols for TMS: high frequency\, theta-burst\, low frequency\, bilateral\, alternative brain targets\, rescue treatment\, and maintenance treatment.\nA revised lecture on TMS risks and their prevention and management\, including seizure protocol review.\nHands-on training on coil location placement & motor threshold determination with multiple TMS devices.\nA review of promising indications beyond depression\, including\, obsessive compulsive disorder\, smoking cessation\, migraine\, post-traumatic stress disorder\, anxiety\, and pain.\nAn extended Q&A Panel with all PULSES faculty and special guests.\n\nRegister
URL:https://clinicaltmssociety.org/event/pulses-providence/
CATEGORIES:PULSES
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2026/06/26-28-September-2025-2.png
END:VEVENT
END:VCALENDAR